BACKGROUND: Type I and II inosine monophosphate dehydrogenases (IMPDH) are the targets of mycophenolic acid (MPA), a widely used immunosuppressant. The aims of this study were: to check the presence of controversial polymorphisms in the IMPDH II gene; to look for new ones; and to investigate potential associations between the most frequent SNPs in both IMPDH genes and clinical outcome in renal transplant recipients. METHODS: The DNA and clinical data of 456 patients from two clinical trials were collected. We sequenced the IMPDH II gene in 80 patients and we genotyped the 456 patients' DNA for the IMPDH II rs4974081, rs11706052, 787C>T and the IMPDH I rs2278293 and rs2278294 SNPs, all of which were earlier reported to be potentially involved in MPA treatment related outcome. We investigated the associations of biopsy proven acute rejection (BPAR), leucopenia, cytomegalovirus infections and other infections with these IMPDH polymorphisms, as well as with demographic, biological and treatment data using multivariate analysis. RESULTS: Many IMPDH II variant alleles referenced in Genbank were not detected and no new polymorphisms were identified. In the whole group of 456 patients, the IMPDH I rs2278294 SNP was associated with a lower risk of BPAR and a higher risk of leucopenia over the first year post-transplantation. No other IMPDH I or IMPDH II polymorphism was significantly associated with any clinical outcome. Interestingly, calcineurin inhibitor and MPA exposures below the therapeutic range increased the risk of BPAR. Cytomegalovirus infection was the factor most closely linked with leucopenia, whereas tacrolimus was associated with fewer infections than cyclosporine. CONCLUSION: IMPDH II genotyping may not improve MPA treatment outcome over the first year post-transplantation, in contrast to MPA and calcineurine inhibitor therapeutic drug monitoring and IMPDH I genotyping.
BACKGROUND: Type I and II inosine monophosphate dehydrogenases (IMPDH) are the targets of mycophenolic acid (MPA), a widely used immunosuppressant. The aims of this study were: to check the presence of controversial polymorphisms in the IMPDH II gene; to look for new ones; and to investigate potential associations between the most frequent SNPs in both IMPDH genes and clinical outcome in renal transplant recipients. METHODS: The DNA and clinical data of 456 patients from two clinical trials were collected. We sequenced the IMPDH II gene in 80 patients and we genotyped the 456 patients' DNA for the IMPDH IIrs4974081, rs11706052, 787C>T and the IMPDH Irs2278293 and rs2278294 SNPs, all of which were earlier reported to be potentially involved in MPA treatment related outcome. We investigated the associations of biopsy proven acute rejection (BPAR), leucopenia, cytomegalovirus infections and other infections with these IMPDH polymorphisms, as well as with demographic, biological and treatment data using multivariate analysis. RESULTS: Many IMPDH II variant alleles referenced in Genbank were not detected and no new polymorphisms were identified. In the whole group of 456 patients, the IMPDH Irs2278294 SNP was associated with a lower risk of BPAR and a higher risk of leucopenia over the first year post-transplantation. No other IMPDH I or IMPDH II polymorphism was significantly associated with any clinical outcome. Interestingly, calcineurin inhibitor and MPA exposures below the therapeutic range increased the risk of BPAR. Cytomegalovirus infection was the factor most closely linked with leucopenia, whereas tacrolimus was associated with fewer infections than cyclosporine. CONCLUSION:IMPDH II genotyping may not improve MPA treatment outcome over the first year post-transplantation, in contrast to MPA and calcineurine inhibitor therapeutic drug monitoring and IMPDH I genotyping.
Authors: L T Weber; M Shipkova; T Lamersdorf; P D Niedmann; M Wiesel; A Mandelbaum; L B Zimmerhackl; E Schütz; O Mehls; M Oellerich; V W Armstrong; B Tönshoff Journal: J Am Soc Nephrol Date: 1998-08 Impact factor: 10.121
Authors: M D Sintchak; M A Fleming; O Futer; S A Raybuck; S P Chambers; P R Caron; M A Murcko; K P Wilson Journal: Cell Date: 1996-06-14 Impact factor: 41.582
Authors: A Rother; P Glander; E Vitt; D Czock; N von Ahsen; V W Armstrong; M Oellerich; K Budde; R Feneberg; B Tönshoff; L T Weber Journal: Eur J Clin Pharmacol Date: 2012-01-25 Impact factor: 2.953
Authors: Tse-Yu Wu; Brooke L Fridley; Gregory D Jenkins; Anthony Batzler; Liewei Wang; Richard M Weinshilboum Journal: Int Immunopharmacol Date: 2011-03-23 Impact factor: 4.932
Authors: Charles D Varnell; Tsuyoshi Fukuda; Cassie L Kirby; Lisa J Martin; Barry L Warshaw; Hiren P Patel; Deepa H Chand; Gina-Marie Barletta; Scott K Van Why; Rene G VanDeVoorde; Donald J Weaver; Amy Wilson; Priya S Verghese; Alexander A Vinks; Larry A Greenbaum; Jens Goebel; David K Hooper Journal: Pediatr Transplant Date: 2017-09-04
Authors: Vishal Lamba; Katrin Sangkuhl; Kinjal Sanghavi; Alyssa Fish; Russ B Altman; Teri E Klein Journal: Pharmacogenet Genomics Date: 2014-01 Impact factor: 2.089